Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Interchangeability between pneumococcal conjugate vaccines for pediatric use: a systematic literature review.

Nieto Guevara J, Borys D, DeAntonio R, Guzman-Holst A, Hoet B.

Expert Rev Vaccines. 2019 Nov 21:1-12. doi: 10.1080/14760584.2019.1688148. [Epub ahead of print]

PMID:
31751159
2.

Increasing Burden of Hepatitis A in Adolescents and Adults and the Need for Long-Term Protection: A Review from the Indian Subcontinent.

Agrawal A, Singh S, Kolhapure S, Hoet B, Arankalle V, Mitra M.

Infect Dis Ther. 2019 Dec;8(4):483-497. doi: 10.1007/s40121-019-00270-9. Epub 2019 Nov 2. Review.

3.

Would immunization be the same without cross-reactivity?

Vojtek I, Buchy P, Doherty TM, Hoet B.

Vaccine. 2019 Jan 21;37(4):539-549. doi: 10.1016/j.vaccine.2018.12.005. Epub 2018 Dec 24. Review.

4.

Associations between a decreased veterinary antimicrobial use and resistance in commensal Escherichia coli from Belgian livestock species (2011-2015).

Callens B, Cargnel M, Sarrazin S, Dewulf J, Hoet B, Vermeersch K, Wattiau P, Welby S.

Prev Vet Med. 2018 Sep 1;157:50-58. doi: 10.1016/j.prevetmed.2017.10.013. Epub 2017 Oct 26.

5.

Letter to the editor to: Isturiz et al. Streptococcus pneumoniae serotype 19A: worldwide epidemiology. Expert review of vaccines 2017;16(10):1007-27.

Mungall BA, Nieto J, Soumahoro L, Hoet B.

Expert Rev Vaccines. 2018 Aug;17(8):665-668. doi: 10.1080/14760584.2018.1506205. Epub 2018 Aug 3. No abstract available.

PMID:
30067110
6.

Response to: Pneumococcal conjugate vaccines in Latin America: are PCV10 and PCV13 similar in terms of protection against serotype 19A?

Guevara JN, Izurieta P, Hoet B.

Expert Rev Vaccines. 2018 Apr;17(4):283-284. doi: 10.1080/14760584.2018.1459247. Epub 2018 Apr 6. No abstract available.

PMID:
29611439
7.

Stability of an aluminum salt-adjuvanted protein D-conjugated pneumococcal vaccine after exposure to subzero temperatures.

Fortpied J, Wauters F, Rochart C, Hermand P, Hoet B, Moniotte N, Vojtek I.

Hum Vaccin Immunother. 2018 May 4;14(5):1243-1250. doi: 10.1080/21645515.2017.1421878. Epub 2018 Feb 12.

8.

Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution.

Izurieta P, Bahety P, Adegbola R, Clarke C, Hoet B.

Expert Rev Vaccines. 2018 Jun;17(6):479-493. doi: 10.1080/14760584.2018.1413354. Epub 2018 Jun 29. Review.

PMID:
29241390
9.

Impact of pneumococcal conjugate vaccines on otitis media: A review of measurement and interpretation challenges.

Vojtek I, Nordgren M, Hoet B.

Int J Pediatr Otorhinolaryngol. 2017 Sep;100:174-182. doi: 10.1016/j.ijporl.2017.07.009. Epub 2017 Jul 11. Review.

10.

A reflection on invasive pneumococcal disease and pneumococcal conjugate vaccination coverage in children in Southern Europe (2009-2016).

Moreira M, Castro O, Palmieri M, Efklidou S, Castagna S, Hoet B.

Hum Vaccin Immunother. 2017 Jun 3;13(6):1-12. doi: 10.1080/21645515.2016.1263409. Epub 2016 Dec 20. Review.

11.

Response to Wu et al. - Cost-effectiveness analysis of infant pneumococcal vaccination in Malaysia and Hong Kong.

Varghese L, Mungall B, Zhang XH, Hoet B.

Hum Vaccin Immunother. 2016 Oct 2;12(10):2675-2680. doi: 10.1080/21645515.2016.1192738. Epub 2016 Jul 26.

12.

Impact of the introduction of the pneumococcal conjugate vaccine in the Brazilian routine childhood national immunization program.

Moreira M, Cintra O, Harriague J, Hausdorff WP, Hoet B.

Vaccine. 2016 May 27;34(25):2766-78. doi: 10.1016/j.vaccine.2016.04.006. Epub 2016 Apr 22. Review.

13.

Further available immunization option to prevent pneumococcal disease.

Vojtek I, Hoet B.

F1000Res. 2015 Jan 7;4:3. doi: 10.12688/f1000research.5990.1. eCollection 2015.

14.

Predicting the impact of new pneumococcal conjugate vaccines: serotype composition is not enough.

Hausdorff WP, Hoet B, Adegbola RA.

Expert Rev Vaccines. 2015 Mar;14(3):413-28. doi: 10.1586/14760584.2015.965160. Epub 2014 Sep 30. Review.

PMID:
25266168
15.

Carriage of Streptococcus pneumoniae and other respiratory bacterial pathogens in low and lower-middle income countries: a systematic review and meta-analysis.

Adegbola RA, DeAntonio R, Hill PC, Roca A, Usuf E, Hoet B, Greenwood BM.

PLoS One. 2014 Aug 1;9(8):e103293. doi: 10.1371/journal.pone.0103293. eCollection 2014. Review.

16.

Immunogenicity of HBV vaccine during stated shelf-life.

Gloriani NG, Srinivasa K, Bock HL, Hoet B.

Southeast Asian J Trop Med Public Health. 2010 Jul;41(4):876-82.

PMID:
21073062
17.

Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A?

Hausdorff WP, Hoet B, Schuerman L.

BMC Pediatr. 2010 Feb 2;10:4. doi: 10.1186/1471-2431-10-4. Review.

18.

Long-term immunogenicity of preservative-free hepatitis B vaccine formulations in adults.

Van Damme P, von Sonnenburg F, Hatz C, Hoet B, Lefevre I, Leyssen M.

J Med Virol. 2009 Oct;81(10):1710-5. doi: 10.1002/jmv.21568.

PMID:
19697416
19.

Prevention of otitis media: now a reality?

Schuerman L, Borys D, Hoet B, Forsgren A, Prymula R.

Vaccine. 2009 Sep 25;27(42):5748-54. doi: 10.1016/j.vaccine.2009.07.070. Epub 2009 Aug 8. Review.

PMID:
19666154
21.

Long-term benefit of hepatitis B vaccination among children in Thailand with transient hepatitis B virus infection who were born to hepatitis B surface antigen-positive mothers.

Poovorawan Y, Chongsrisawat V, Theamboonlers A, Srinivasa K, Hutagalung Y, Bock HL, Hoet B.

J Infect Dis. 2009 Jul 1;200(1):33-8. doi: 10.1086/599331.

PMID:
19473096
22.

Booster vaccination of toddlers with reduced antigen content diphtheria -- tetanus -- acellular pertussis vaccine.

Nolan T, Ruff TA, Lambert SB, Buttery J, O'Grady KA, Streeton C, Hoet B, Bock HL.

Vaccine. 2009 Apr 21;27(18):2410-3. doi: 10.1016/j.vaccine.2009.02.065. Epub 2009 Feb 27.

PMID:
19368781
23.

Booster vaccination of adults with reduced-antigen-content diphtheria, Tetanus and pertussis vaccine: immunogenicity 5 years post-vaccination.

McIntyre PB, Burgess MA, Egan A, Schuerman L, Hoet B.

Vaccine. 2009 Feb 11;27(7):1062-6. doi: 10.1016/j.vaccine.2008.11.102. Epub 2008 Dec 16.

PMID:
19095033
24.

Guidelines for collection, analysis and presentation of vaccine safety data in surveillance systems.

Bonhoeffer J, Bentsi-Enchill A, Chen RT, Fisher MC, Gold MS, Hartman K, Heininger U, Hoet B, Jefferson T, Khuri-Bulos N, Kohl K, Marcy SM, Nalin D, Pless R, Sanabria-Rojas H, Sleeman K, Wise R; Brighton Collaboration Methods Working Group.

Vaccine. 2009 Apr 6;27(16):2289-97. doi: 10.1016/j.vaccine.2008.11.035. Epub 2008 Dec 4. No abstract available.

PMID:
19061929
25.

Guidelines for collection, analysis and presentation of vaccine safety data in pre- and post-licensure clinical studies.

Bonhoeffer J, Bentsi-Enchill A, Chen RT, Fisher MC, Gold MS, Hartman K, Heininger U, Hoet B, Jefferson T, Khuri-Bulos N, Kohl KS, Marcy SM, Nalin D, Pless R, Sanabria-Rojas H, Sleeman K, Wise R; Brighton Collaboration Methods Working Group.

Vaccine. 2009 Apr 6;27(16):2282-8. doi: 10.1016/j.vaccine.2008.11.036. Epub 2008 Dec 3. No abstract available.

PMID:
19056451
26.

A local reaction at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data.

Gidudu J, Kohl KS, Halperin S, Hammer SJ, Heath PT, Hennig R, Hoet B, Rothstein E, Schuind A, Varricchio F, Walop W; Brighton Collaboration Local Reactions Working Group for a Local Reaction at or near Injection Site.

Vaccine. 2008 Dec 9;26(52):6800-13. doi: 10.1016/j.vaccine.2008.10.006. Epub 2008 Oct 23.

PMID:
18950670
27.

Hepatitis B immunisation in travellers: poor risk perception and inadequate protection.

Zuckerman JN, Hoet B.

Travel Med Infect Dis. 2008 Sep;6(5):315-20. doi: 10.1016/j.tmaid.2008.05.001.

PMID:
18760256
28.

Immunogenicity and reactogenicity of acellular pertussis booster vaccines in children: standard pediatric versus a reduced-antigen content formulation.

Meyer CU, Habermehl P, Knuf M, Hoet B, Wolter J, Zepp F.

Hum Vaccin. 2008 May-Jun;4(3):203-9. Epub 2010 May 11.

PMID:
18382142
29.

Booster vaccination at 6-8 years of age with a reduced antigen content dTpa-IPV vaccine is immunogenic and safe after priming with whole-cell pertussis vaccine.

Lin TY, Wang YH, Huang YC, Chiu CH, Lin PY, Tang H, Hoet B, Bock HL.

Hum Vaccin. 2008 Jan-Feb;4(1):50-3. Epub 2007 Aug 27.

PMID:
18376147
30.

Long-term antibody persistence induced by a combined hepatitis A and B vaccine in children and adolescents.

Diaz-Mitoma F, Law B, Subramanya A, Hoet B.

Vaccine. 2008 Mar 25;26(14):1759-63. doi: 10.1016/j.vaccine.2008.01.014. Epub 2008 Feb 4.

PMID:
18336963
31.

A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients.

Kong NC, Beran J, Kee SA, Miguel JL, Sánchez C, Bayas JM, Vilella A, Calbo-Torrecillas F, López de Novales E, Srinivasa K, Stoffel M, Hoet B.

Kidney Int. 2008 Apr;73(7):856-62. Epub 2007 Dec 26.

32.

Primary vaccination of adults with reduced antigen-content diphtheria-tetanus-acellular pertussis or dTpa-inactivated poliovirus vaccines compared to diphtheria-tetanus-toxoid vaccines.

Theeten H, Rümke H, Hoppener FJ, Vilatimó R, Narejos S, Van Damme P, Hoet B.

Curr Med Res Opin. 2007 Nov;23(11):2729-39.

PMID:
17897485
33.

Ten-year antibody persistence induced by hepatitis A and B vaccine (Twinrix) in adults.

Van Herck K, Leroux-Roels G, Van Damme P, Srinivasa K, Hoet B.

Travel Med Infect Dis. 2007 May;5(3):171-5. Epub 2006 Sep 20.

PMID:
17448944
34.

Unexplained sudden death, including sudden infant death syndrome (SIDS), in the first and second years of life: case definition and guidelines for collection, analysis, and presentation of immunization safety data.

Jorch G, Tapiainen T, Bonhoeffer J, Fischer TK, Heininger U, Hoet B, Kohl KS, Lewis EM, Meyer C, Nelson T, Sandbu S, Schlaud M, Schwartz A, Varricchio F, Wise RP; Brighton Collaboration Unexplained Sudden Death Working Group.

Vaccine. 2007 Aug 1;25(31):5707-16. Epub 2007 Mar 12. No abstract available.

PMID:
17408816
35.

Immunogenicity, reactogenicity and safety of two-dose versus three-dose (standard care) hepatitis B immunisation of healthy adolescents aged 11-15 years: a randomised controlled trial.

Heron L, Selnikova O, Moiseieva A, Van Damme P, van der Wielen M, Levie K, Hoet B, Stoffel M.

Vaccine. 2007 Apr 12;25(15):2817-22. Epub 2006 Dec 29.

PMID:
17276552
36.

Booster vaccination and 1-year follow-up of 4-8-year-old children with a reduced-antigen-content dTpa-IPV vaccine.

Sänger R, Behre U, Krause KH, Loch HP, Soemantri P, Herrmann D, Schmitz-Hauss E, Wolter J, Hoet B.

Eur J Pediatr. 2007 Dec;166(12):1229-36. Epub 2007 Jan 18.

PMID:
17235521
37.

Antibody persistence and immune memory elicited by combined hepatitis A and B vaccination in older adults.

Höhler T, Groeger-Bicanic G, Hoet B, Stoffel M.

Vaccine. 2007 Feb 9;25(8):1503-8. Epub 2006 Oct 27.

PMID:
17097774
38.

Nigerian medical students are at risk for hepatitis B infection.

Odusanya OO, Meurice FP, Hoet B.

Trans R Soc Trop Med Hyg. 2007 May;101(5):465-8. Epub 2006 Sep 29.

PMID:
17011004
39.

A mathematical model of hepatitis a transmission in the United States indicates value of universal childhood immunization.

Van Effelterre TP, Zink TK, Hoet BJ, Hausdorff WP, Rosenthal P.

Clin Infect Dis. 2006 Jul 15;43(2):158-64. Epub 2006 Jun 12.

PMID:
16779741
40.
41.

Epidemiological typing of Bordetella pertussis isolates: recommendations for a standard methodology.

Mooi FR, Hallander H, Wirsing von König CH, Hoet B, Guiso N.

Eur J Clin Microbiol Infect Dis. 2000 Mar;19(3):174-81.

PMID:
10795589
42.

Prevalence of herds with young sows seropositive to pseudorabies (Aujeszky's disease) in northern Belgium.

Boelaert F, Deluyker H, Maes D, Godfroid J, Raskin A, Varewijck H, Pensaert M, Nauwynck H, Castryck F, Miry C, Robijns JM, Hoet B, Segers E, Van Vlaenderen I, Robert A, Koenen F.

Prev Vet Med. 1999 Aug 23;41(4):239-55.

PMID:
10530424
43.

An echistatin-like Arg-Gly-Asp (RGD)-containing sequence in the heavy chain CDR3 of a murine monoclonal antibody that inhibits human platelet glycoprotein IIb/IIIa function.

Deckmyn H, Stanssens P, Hoet B, Declerck PJ, Lauwereys M, Gansemans Y, Tornai I, Vermylen J.

Br J Haematol. 1994 Jul;87(3):562-71.

PMID:
7993797
45.

Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group.

Verstraete M, Nurmohamed M, Kienast J, Siebeck M, Silling-Engelhardt G, Büller H, Hoet B, Bichler J, Close P.

J Am Coll Cardiol. 1993 Oct;22(4):1080-8.

46.

Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39393) in healthy volunteers.

Marbet GA, Verstraete M, Kienast J, Graf P, Hoet B, Tsakiris DA, Silling-Engelhardt G, Close P.

J Cardiovasc Pharmacol. 1993 Sep;22(3):364-72.

PMID:
7504125
47.

Sodium fluoride induced activation of phospholipase C in intact human platelets does not depend on ADP, PAF or arachidonate products.

Pfliegler G, Arnout J, Kienast J, Wittevrongel C, Hoet B, Deckmyn H, Vermylen J.

Thromb Res. 1993 Mar 15;69(6):541-5. No abstract available.

PMID:
8503122
48.

Grey platelet syndrome: evidence for alpha-granule localization of the platelet plasminogen activator inhibitor-1 pool.

Vermylen C, Vermylen J, Hoet B, Scheiff JM, Ninane J, Cornu G.

Pediatr Hematol Oncol. 1991 Apr-Jun;8(2):111-20.

PMID:
1713778
49.
50.

Pharmacological manipulation of the thromboxane pathway in blood platelets.

Hoet B, Deckmyn H, Arnout J, Vermylen J.

Blood Coagul Fibrinolysis. 1990 Jun;1(2):225-33. Review.

PMID:
2130935

Supplemental Content

Support Center